FDA Reshapes Drug Testing Approach - Summary - MDSpire
FDA & Government News

FDA Reshapes Drug Testing Approach

The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.

Share

The FDA has made significant strides in reducing animal testing for preclinical safety studies, following its April 2025 roadmap. This initiative aims to phase out animal testing by employing alternative methods that demonstrate equal or better predictive performance. Commissioner Marty Makary emphasized the dual benefits of more accurate drug testing and reduced research costs, ultimately aiming to lower drug prices for Americans. The FDA has introduced new guidance to limit nonhuman primate testing and has qualified an AI tool for drug development, enhancing collaboration with international regulators and NIH to advance these methodologies.

Original Source(s)

FDA Reshapes Drug Testing Approach

  • by Kathryn Wighton

  • April 20, 2026

Related Content

The Tenure Clock Doesn’t Pause for Politics

Academic institutions need a structured response to federal research defunding

The Secrets of the Gut

Going beyond the gut: why microbiome testing is the next big thing in drug development

  • April 20, 2026

  • 6 min
ACP Updates Breast Cancer Screening Guidance

Biennial mammography recommended for ages 50 to 74 years, with shared decision-making outside that range.